# Kite, A Gilead Company clinical trials: 40 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 40 trials with Kite, A Gilead Company as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Kite, A Gilead Company: 40 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/kite-a-gilead-company

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07903506 | To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903506) |
| October 21, 2026 | NCT07887672 | A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887672) |
| March 18, 2026 | NCT07479797 | Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma... | Kite, A Gilead Company | Phase 3 | Active not recruiting | Relapsed or Refractory Large B-cell Lymphoma | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07479797) |
| December 26, 2025 | NCT07304154 | Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment | Kite, A Gilead Company | Phase 1 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07304154) |
| June 26, 2025 | NCT07038447 | A Study of KITE-363 in Participants With Refractory Autoimmune Diseases | Kite, A Gilead Company | Phase 1 | Enrolling by invitation | Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07038447) |
| October 4, 2024 | NCT06626919 | Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases | Kite, A Gilead Company | Phase 1 | Recruiting | Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06626919) |
| August 6, 2024 | NCT06539338 | A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back... | Kite, A Gilead Company | Phase 1 | Active not recruiting | Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06539338) |
| May 14, 2024 | NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Active not recruiting | Multiple Myeloma | 452 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06413498) |
| February 12, 2024 | NCT06253663 | Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute... | Kite, A Gilead Company | Phase 2 | Active not recruiting | Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06253663) |
| October 12, 2023 | NCT06079164 | Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma | Kite, A Gilead Company | Phase 1 | Active not recruiting | Relapsed/Refractory Large B-cell Lymphoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06079164) |
| March 20, 2023 | NCT05776160 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | Kite, A Gilead Company | Not applicable | Available | Large B-cell Lymphoma, Follicular Lymphoma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05776160) |
| March 20, 2023 | NCT05776134 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | Kite, A Gilead Company | Not applicable | Available | Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05776134) |
| November 4, 2022 | NCT05605899 | Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell... | Kite, A Gilead Company | Phase 3 | Active not recruiting | High-risk Large B-cell Lymphoma (LBCL) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05605899) |
| September 13, 2022 | NCT05537766 | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies | Kite, A Gilead Company | Phase 2 | Terminated | Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory... | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05537766) |
| July 15, 2022 | NCT05459571 | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | Kite, A Gilead Company | Phase 2 | Completed | Relapsed or Refractory Large B-cell Lymphoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05459571) |
| July 13, 2022 | NCT05457010 | Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic... | Kite, A Gilead Company | Phase 1 | Active not recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05457010) |
| May 31, 2022 | NCT05396885 | Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Kite, A Gilead Company | Phase 2 | Active not recruiting | Multiple Myeloma | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05396885) |
| May 12, 2022 | NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | Kite, A Gilead Company | Phase 3 | Active not recruiting | Relapsed/Refractory Follicular Lymphoma | 231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05371093) |
| September 13, 2021 | NCT05041309 | Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies | Kite, A Gilead Company | Observational | Enrolling by invitation | Solid and Hematological Malignancies, Autoimmune Diseases | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05041309) |
| August 4, 2021 | NCT04989803 | Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma | Kite, A Gilead Company | Phase 1/2 | Active not recruiting | Relapsed and/or Refractory B-cell Lymphoma | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04989803) |
| May 10, 2021 | NCT04880434 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) | Kite, A Gilead Company | Phase 2 | Completed | Relapsed/Refractory Mantle Cell Lymphoma | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04880434) |
| March 9, 2021 | NCT04789408 | Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | Kite, A Gilead Company | Phase 1 | Terminated | Acute Myeloid Leukemia | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04789408) |
| March 19, 2020 | NCT04314843 | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma | Kite, A Gilead Company | Phase 1 | Terminated | Relapsed/Refractory Large B-cell Lymphoma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04314843) |
| November 14, 2019 | NCT04162756 | Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies | Kite, A Gilead Company | Not applicable | Approved for marketing | Relapse/Refractory Mantle Cell Lymphoma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04162756) |
| November 7, 2019 | NCT04155749 | Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | Kite, A Gilead Company | Phase 1 | Active not recruiting | Relapsed and Refractory Multiple Myeloma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04155749) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 5 |
| Phase 2 | 9 |
| Phase 3 | 7 |
| Not applicable | 4 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Active not recruiting | 11 |
| Completed | 11 |
| Terminated | 8 |
| Approved for marketing | 2 |
| Enrolling by invitation | 2 |
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Available | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Recurrence | 13 |
| Multiple Myeloma | 7 |
| Lymphoma, Mantle-Cell | 5 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Lymphoma, B-Cell | 3 |
| Lymphoma, Follicular | 3 |
| Leukemia, Myeloid, Acute | 2 |
| Autoimmune Diseases | 2 |
| Myasthenia Gravis | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Ovarian Neoplasms | 1 |
| Fallopian Tube Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Myelodysplastic Syndromes | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Lupus Nephritis | 1 |
| Scleroderma, Systemic | 1 |
| Myositis | 1 |
| Neoplasms, Plasma Cell | 1 |
| Waldenstrom Macroglobulinemia | 1 |
| Burkitt Lymphoma | 1 |
| Leukemia, Hairy Cell | 1 |
| Muscular Diseases | 1 |
| Neuromuscular Manifestations | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Livestock feed and supply stores in the United States](https://specstream.ai/data/businesses/livestock-feed-and-supply-stores/united-states)
- [Video production companies in the United States](https://specstream.ai/data/businesses/video-production-companies/united-states)
- [Environmental services in the United States](https://specstream.ai/data/businesses/environmental-services/united-states)
- [Portuguese restaurants in the United States](https://specstream.ai/data/businesses/portuguese-restaurants/united-states)
- [Bars in the United States](https://specstream.ai/data/businesses/bars/united-states)
- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
